Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Multiple Myeloma 1 Colorectal Neoplasms 1

Interventions

Paclitaxel 69 Bevacizumab 62 Carboplatin 53 pembrolizumab 46 olaparib 32 Specimen Handling 27 Gemcitabine 27 Cyclophosphamide 26 Magnetic Resonance Spectroscopy 24 liposomal doxorubicin 22 Cisplatin 21 niraparib 20 Taxes 18 Nivolumab 18 fludarabine 17 Topotecan 17 Biopsy 17 Doxorubicin 14 Immunoglobulin G 12 Fulvestrant 12 Disulfides 12 Oxaliplatin 10 mirvetuximab soravtansine 9 durvalumab 9 aldesleukin 9 Surveys and Questionnaires 9 Ipilimumab 9 Fluorouracil 9 Blood Specimen Collection 9 cemiplimab 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Neoplasms × Maximum Tolerated Dose × 1 year × Clear all

NCT06976892 2025-08-13

IDOL

Institute of Cancer Research, United Kingdom

Phase 1 Recruiting

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡